Alkem Laboratories Limited has informed the Exchange about US FDA Inspection at Company s manufacturing facility located at Amaliya, Daman
ALKEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
US FDA conducted a routine inspection at Alkem Laboratories' manufacturing facility in Amaliya, Daman from April 20 to May 1, 2026. At the conclusion of the inspection, the company received Form 483 with seven observations. Form 483 is issued when FDA investigators identify conditions that may constitute violations of the Food, Drug, and Cosmetic Act. The company has stated it will address all observations within the stipulated timeframe. This is a disclosure of an ongoing regulatory matter without any indication of final enforcement action such as a warning letter or import alert.
Form 483 observations indicate regulatory scrutiny and areas needing correction. While 7 observations suggest moderate compliance gaps, the company has committed to addressing them. This could create near-term investor concern given Alkem's US revenue exposure, though no official enforcement action has been taken yet.